TY - JOUR
T1 - Low-Level Laser Therapy Ameliorates Disease Progression in a Mouse Model of Alzheimer’s Disease
AU - Farfara, Dorit
AU - Tuby, Hana
AU - Trudler, Dorit
AU - Doron-Mandel, Ella
AU - Maltz, Lidya
AU - Vassar, Robert J.
AU - Frenkel, Dan
AU - Oron, Uri
N1 - Publisher Copyright:
© 2014, Springer Science+Business Media New York.
PY - 2014/2
Y1 - 2014/2
N2 - Low–level laser therapy (LLLT) has been used to treat inflammation, tissue healing, and repair processes. We recently reported that LLLT to the bone marrow (BM) led to proliferation of mesenchymal stem cells (MSCs) and their homing in the ischemic heart suggesting its role in regenerative medicine. The aim of the present study was to investigate the ability of LLLT to stimulate MSCs of autologous BM in order to affect neurological behavior and β-amyloid burden in progressive stages of Alzheimer’s disease (AD) mouse model. MSCs from wild-type mice stimulated with LLLT showed to increase their ability to maturate towards a monocyte lineage and to increase phagocytosis activity towards soluble amyloid beta (Aβ). Furthermore, weekly LLLT to BM of AD mice for 2 months, starting at 4 months of age (progressive stage of AD), improved cognitive capacity and spatial learning, as compared to sham-treated AD mice. Histology revealed a significant reduction in Aβ brain burden. Our results suggest the use of LLLT as a therapeutic application in progressive stages of AD and imply its role in mediating MSC therapy in brain amyloidogenic diseases.
AB - Low–level laser therapy (LLLT) has been used to treat inflammation, tissue healing, and repair processes. We recently reported that LLLT to the bone marrow (BM) led to proliferation of mesenchymal stem cells (MSCs) and their homing in the ischemic heart suggesting its role in regenerative medicine. The aim of the present study was to investigate the ability of LLLT to stimulate MSCs of autologous BM in order to affect neurological behavior and β-amyloid burden in progressive stages of Alzheimer’s disease (AD) mouse model. MSCs from wild-type mice stimulated with LLLT showed to increase their ability to maturate towards a monocyte lineage and to increase phagocytosis activity towards soluble amyloid beta (Aβ). Furthermore, weekly LLLT to BM of AD mice for 2 months, starting at 4 months of age (progressive stage of AD), improved cognitive capacity and spatial learning, as compared to sham-treated AD mice. Histology revealed a significant reduction in Aβ brain burden. Our results suggest the use of LLLT as a therapeutic application in progressive stages of AD and imply its role in mediating MSC therapy in brain amyloidogenic diseases.
KW - Alzheimer’s Disease (AD)
KW - Amyloid beta (Aβ) bone marrow (BM)
KW - Low-level-laser therapy (LLLT)
KW - Mesenchymal stem cells (MSC)
UR - http://www.scopus.com/inward/record.url?scp=84933075357&partnerID=8YFLogxK
U2 - 10.1007/s12031-014-0354-z
DO - 10.1007/s12031-014-0354-z
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:84933075357
SN - 0895-8696
VL - 55
SP - 430
EP - 436
JO - Journal of Molecular Neuroscience
JF - Journal of Molecular Neuroscience
IS - 2
ER -